 |
|
|
| |
Week 96 safety and efficacy of the novel
HIV-1 attachment inhibitor prodrug fostemsavir
in heavily treatment-experienced participants
infected with multi-drug-resistant HIV-1 (BRIGHTE Study)
|
| |
| |
10th IAS Conference on HIV Science (IAS 2019), 21-24 July 2019, Mexico City, Mexico
M. Lataillade,1 J. Lalezari,2 J. Aberg,3 J.-M. Molina,4 M. Kozal,5 P. Cahn,6 M. Thompson,7
R. Diaz,8 A. Castagna,9 M. Gummel,10 M. Gartland,11 A. Pierce,11 P. Ackerman1 and C. Llamoso1
1ViiV Healthcare, Branford, CT, USA. 2Quest Research, San Francisco, CA, USA. 3Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4Hospital Saint-Louis, Assistance Publique Hopitaux de Paris, Paris, France. 5Yale University School of Medicine, New Haven, CT, USA. 6Fundacion Huesped, Buenos Aires, Argentina. 7AIDS Research Consortium of Atlanta, Atlanta, GA, USA. 8Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. 9Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Milan, Italy. 10GlaxoSmithKline, Upper Providence, PA, USA. 11ViiV Healthcare, Research Triangle Park, NC, USA.
|
| |
|
|
|
|
|
